Related Experiment Video
Updated: Feb 25, 2026
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Gefitinib versus Docetaxel in Treated Non-small-cell Lung Cancer: A Meta-analysis
Bing Wang1, Zhanjie Zuo2, Fang Li1
1Department of Thoracic Surgical Oncology, Department of Thoracic Surgical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing100021, China.
Abstract:
The objective of this study was to perform a meta-analysis to evaluate the efficacy and toxicity of gefitinib and docetaxel in treated patients with non-small-cell lung cancer (NSCLC).
Methods:
A literature search was performed using PubMed and CNKI databases for relevant keywords and the Medical Subject Headings. After further full-text screening, 10 clinical trials were included in the final meta-analysis. Specific odds ratios (OR) and confidence intervals were calculated.
Results:
The outcomes of treatment efficacy included disease control rates, quality-of-life improvement rates, 3~4 grade adverse events. Comparing gefitinib to docetaxel for NSCLC patients, the pooled odds ratios (OR) of disease control rates was 1.09, (95% confidential index [CI] = 0.84-1.43), the pooled OR of quality-of-life improvement rates was 2.49, (95% CI = 1.77-3.49), the pooled OR of 3~4 grade adverse events was 0.49, (95% CI = 0.32-0.75).
Conclusion:
Gefitinib was found to significantly improve patients' quality-of-life and obviously decrease patients' adverse events of 3~4 grade.There is no difference of disease control rates between gefitinib and docetaxel.
More Related Videos
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
06:44Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
